SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is currently trending following the announcement of a binding agreement to deploy AI-driven GPU infrastructure in India, an initiative projected to generate significant long-term revenue. While the stock has seen a wave of optimism regarding its contract pipeline and AI infrastructure role, community sentiment remains divided as investors debate the conversion timeline of these major deals versus historical transparency concerns and ongoing market volatility.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is surging following a massive five-year AI infrastructure agreement with Meta valued at up to $27 billion, further cementing its position as a primary AI hyperscaler. The community is actively debating the stock's long-term valuation against its recent backlog expansion and price action, with many investors highlighting the rare 'three-counterparty validation' from Microsoft, Meta, and NVIDIA as a key driver of institutional confidence.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is surging as investors pile in ahead of next week's highly anticipated earnings report, fueled by bullish analyst price target hikes and sustained demand for AI-driven memory chips. While the stock shows significant momentum, the community remains divided between those expecting a 'blowout' post-earnings rally toward new highs and others wary of potential volatility stemming from broader macroeconomic uncertainty and geopolitical tensions.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

CytomX Therapeutics is seeing significant investor attention driven by positive clinical data updates for its Varsetatug Masetecan (CX-2051) candidate in colorectal cancer, despite some community skepticism regarding recent financial results. Traders are actively monitoring the stock for potential momentum as the company progresses toward upcoming clinical milestones and expansion trials, with many discussions focusing on its long-term potential as a buyout candidate.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is gaining significant momentum and trending as investors react to the completed acquisition of Astria Therapeutics and prepare for upcoming data presentations at the AAAAI annual meeting. The community is actively discussing the stock's potential valuation floor, ongoing high short interest, and the disruptive potential of the navenibart pipeline program to trigger a reversal in the long-term price trend.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is generating intense debate as investors react to a treasury update showing holdings of $11.5 billion in cash and crypto, alongside a strategic funding round and board appointments tied to Eightco Holdings. While some community members view the company's aggressive acquisition of Ethereum and moonshot investments as a long-term catalyst for institutional value, others remain focused on concerns regarding share dilution and the stock's performance relative to its underlying assets.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is experiencing intense volatility and speculative fervor as traders weigh the impact of an escalating conflict in the Middle East and ongoing disruptions in the Strait of Hormuz. The community is deeply divided, with bulls pointing to supply risks and potential military escalations as catalysts for further gains, while bears are aggressively shorting the asset, anticipating a sharp reversal once diplomatic efforts or strategic reserve releases begin to stabilize the market.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is currently a focal point for intense market debate as investors weigh the stock's massive year-to-date gains against concerns over AI-driven memory chip supply constraints and broader geopolitical tensions. While bulls highlight structural demand and upcoming industry catalysts, the community remains deeply divided, with high-profile short sellers and risk-averse traders clashing over whether the current valuation is sustainable or due for a sharp correction.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp is surging amid heightened institutional interest and bullish sentiment surrounding its strategic role as a domestic producer of critical minerals for the U.S. defense sector. Investors are closely monitoring the stock as it approaches a high-profile NYSE uplisting, with community discussion focused on recent government contracts, tungsten resource potential, and significant short interest.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore Corp. (SOC) is trending following a federal directive issued under the Defense Production Act, which mandates the resumption of hydrocarbon transportation through the Santa Ynez Pipeline System to address energy supply risks. While the community is actively debating the stock's potential for a major short squeeze and the implications of federal versus state legal clashes, traders are closely monitoring upcoming production milestones and the company's ability to commence first oil sales by April.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$TRDA great ride so far and guidance in &#39;26 is much welcomed.

$TRDA I’ve started a position at these levels. Clinical stage biotech with minimal spend, partnership and licensing revenues from a strong rare disease biotech player trading below cash. Another potential headwind that seems to have missed entrada so far is that they’re delivering a gene therapy without the potential/perceived harm of AAV viral vectors (eg $SRPT). Will buy/build more, if it dips further.

My only critique is that they don’t give guidance on future trial readouts in their corporate pdf so not sure when the catalyst events will take place.